Email ID
Password
Scrip   
Cephalon's Treanda could become new standard in newly diagnosed non-Hodgkin's lymphoma
09 December 2009
Malini Guha

Cephalon's new chemotherapy drug Treanda (bendamustine) has the potential to become a new standard first-line treatment for indolent non-Hodgkin's lymphoma (NHL) in combination with rituximab, according to experts presenting data from an independent, investigator-sponsored Phase III trial...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36